STAT5B and nasopharyngeal carcinoma: Although many studies suggested the anticancer ability of silibinin and its ability to inhibit PD-L1 expression in nasopharyngeal cancer [35], its possible mechanism behind the STAT5 pathway and PD-L1 expression in NSCLC are still unknown.